Adrian Alegre

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9763576/publications.pdf

Version: 2024-02-01

115 papers	5,456 citations	126708 33 h-index	82410 72 g-index
118 all docs	118 docs citations	118 times ranked	4681 citing authors

#	Article	IF	Citations
1	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2013, 14, 1055-1066.	5.1	710
2	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet, The, 2019, 394, 2096-2107.	6.3	435
3	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood, 2012, 120, 1589-1596.	0.6	429
4	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood, 2006, 108, 2165-2172.	0.6	373
5	High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood, 2012, 119, 687-691.	0.6	274
6	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. Journal of Clinical Oncology, 2008, 26, 5775-5782.	0.8	263
7	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. Journal of Clinical Oncology, 2017, 35, 2900-2910.	0.8	248
8	Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood, 2011, 118, 529-534.	0.6	183
9	Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. Journal of Hematology and Oncology, 2020, 13, 133.	6.9	171
10	The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer, 2010, 116, 3807-3814.	2.0	118
11	Phase II Pethema Trial of Alternating Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients With Multiple Myeloma: Efficacy and Clinical Implications of Tumor Response Kinetics. Journal of Clinical Oncology, 2007, 25, 4452-4458.	0.8	106
12	Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biology of Blood and Marrow Transplantation, 2004, 10, 698-708.	2.0	103
13	Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica, 2010, 95, 1913-1920.	1.7	101
14	Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. British Journal of Haematology, 2000, 109, 438-446.	1.2	100
15	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 757-767.	0.8	98
16	Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. British Journal of Haematology, 2003, 121, 104-108.	1.2	90
17	Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion, 2002, 42, 4-9.	0.8	87
18	Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients. Biology of Blood and Marrow Transplantation, 2007, 13, 1448-1454.	2.0	83

#	Article	IF	Citations
19	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica, 2008, 93, 560-565.	1.7	82
20	Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. British Journal of Haematology, 2000, 109, 138-147.	1.2	69
21	Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood, 2002, 100, 724-727.	0.6	68
22	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica, 2015, 100, 1327-1333.	1.7	68
23	Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica, 2002, 87, 609-14.	1.7	65
24	Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. Biology of Blood and Marrow Transplantation, 2013, 19, 69-74.	2.0	60
25	Bortezomib is an efficient agent in plasma cell leukemias. International Journal of Cancer, 2005, 114, 665-667.	2.3	59
26	Methylene blueâ€photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. British Journal of Haematology, 2008, 143, 39-45.	1.2	57
27	Evaluation of minimal residual disease in multiple myeloma patients by fluorescentâ€polymerase chain reaction: the prognostic impact of achieving molecular response. British Journal of Haematology, 2008, 142, 766-774.	1.2	52
28	Phase 1/1<scp>B</scp> trial of the heat shock protein 90 inhibitor <scp>NVP</scp>â€<scp>AUY</scp>922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer, 2015, 121, 2185-2192.	2.0	51
29	Donor age-related differences in PBPC mobilization with rHuG-CSF. Transfusion, 2001, 41, 201-205.	0.8	50
30	Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma. Leukemia and Lymphoma, 2002, 43, 67-75.	0.6	45
31	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica, 2015, 100, 1334-1339.	1.7	44
32	Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica, 2006, 91, 621-7.	1.7	39
33	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica, 2008, 93, 1001-1008.	1.7	36
34	Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leukemia and Lymphoma, 2012, 53, 1714-1721.	0.6	29
35	Clinical applicability and prognostic significance of molecular response assessed by fluorescentâ€<scp>PCR</scp> of immunoglobulin genes in multiple myeloma. Results from a <scp>GEM</scp>/<scp>PETHEMA</scp> study. British Journal of Haematology, 2013, 163, 581-589.	1.2	27
36	Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 163-167.	1.4	27

#	Article	IF	Citations
37	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica, 2021, 106, 1182-1187.	1.7	27
38	Subgroup analysis of ICARIAâ€MM study in relapsed/refractory multiple myeloma patients with highâ€risk cytogenetics. British Journal of Haematology, 2021, 194, 120-131.	1.2	27
39	Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leukemia and Lymphoma, 2009, 50, 216-222.	0.6	24
40	Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. British Journal of Haematology, 2001, 114, 544-550.	1.2	23
41	Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. European Journal of Haematology, 2011, 87, 281-284.	1.1	23
42	Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials. American Journal of Pathology, 2012, 181, 1870-1878.	1.9	22
43	Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. International Journal of Hematology, 2011, 93, 351-360.	0.7	19
44	Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica, 2012, 97, 616-621.	1.7	19
45	Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. Haematologica, 2015, 100, 1096-102.	1.7	19
46	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica, 2016, 101, 872-878.	1.7	19
47	A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib. Blood, 2010, 116, 307-307.	0.6	19
48	Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica, 2008, 93, 1343-1350.	1.7	18
49	Second Mobilization and Collection of Peripheral Blood Progenitor Cells in Healthy Donors Is Associated with Lower CD34+Cell Yields. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 705-709.	1.8	16
50	Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. Cancer Treatment Reviews, 2012, 38, 1012-1019.	3.4	16
51	Can COVIDâ€19 cause severe neutropenia?. Clinical Case Reports (discontinued), 2020, 8, 3348-3350.	0.2	16
52	Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review. European Journal of Haematology, 2014, 92, 181-188.	1.1	15
53	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer Journal, 2021, 11, 101.	2.8	14
54	Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. Blood, 2019, 134, 581-581.	0.6	14

#	Article	IF	Citations
55	VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study. Blood, 2018, 132, 126-126.	0.6	13
56	Mid term results after bone marrow laser revascularization for treating refractory angina. BMC Cardiovascular Disorders, 2010, 10, 42.	0.7	12
57	OP-106 Horizon â€" Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS. Blood, 2018, 132, 600-600.	0.6	12
58	A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL). Blood, 2018, 132, 1682-1682.	0.6	12
59	Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial. Blood, 2012, 120, 334-334.	0.6	12
60	Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. Blood, 2021, 138, 1829-1829.	0.6	12
61	Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma. Blood, 2008, 112, 867-867.	0.6	11
62	Clonal evolution in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2010, 51, 1142-1143.	0.6	10
63	Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S7275.	0.6	8
64	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 68.	2.8	8
65	Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e33.	0.2	7
66	Patientâ€reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. British Journal of Haematology, 2022, 196, 639-648.	1.2	7
67	Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Current Medical Research and Opinion, 2012, 28, 57-67.	0.9	6
68	Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2008, 112, 3700-3700.	0.6	6
69	A Phase III PETHEMA/GEM Randomized Trial of Postransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,. Blood, 2011, 118, 3962-3962.	0.6	6
70	Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment. Blood, 2011, 118, 991-991.	0.6	5
71	Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia. Oncology and Therapy, 2021, 9, 139-151.	1.0	4
72	Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment. Blood, 2010, 116, 1935-1935.	0.6	4

#	Article	IF	Citations
73	Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience. Blood, 2021, 138, 3775-3775.	0.6	4
74	Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma. HemaSphere, 2020, 4, e380.	1.2	3
75	Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis. Blood, 2019, 134, 1893-1893.	0.6	3
76	Alternating Bortezomib and Dexamethasone as Induction Regimen Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Younger Patients with Multiple Myeloma: Results of a PETHEMA Phase II Trial.. Blood, 2006, 108, 3086-3086.	0.6	3
77	Phase 2 Study Of Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) For Newly Diagnosed Multiple Myeloma (MM). Blood, 2013, 122, 2155-2155.	0.6	3
78	HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S329-S330.	0.2	2
79	Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e352-e353.	0.2	2
80	Clinical Efficacy of Bortezomib Based Therapy in Plasma Cell Leukemias.. Blood, 2007, 110, 2726-2726.	0.6	2
81	Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials. Blood, 2010, 116, 1910-1910.	0.6	2
82	Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience. Blood, 2010, 116, 3045-3045.	0.6	2
83	Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,. Blood, 2011, 118, 3938-3938.	0.6	2
84	Preliminary Experience of the Spanish Compassionate Use Registry of Bendamustine in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood, 2012, 120, 4035-4035.	0.6	2
85	MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (> 65 Years of Age). Blood, 2013, 122, 3198-3198.	0.6	2
86	Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2013, 122, 686-686.	0.6	2
87	Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study. Blood, 2014, 124, 3457-3457.	0.6	2
88	Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma. Blood Cancer Journal, 2021, 11, 169.	2.8	2
89	Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial. Blood, 1999, 94, 1218-1225.	0.6	2
90	Liposomal Doxorubicin in Aggressive B Cell Lymphoma Has Similar Efficacy to the Conventional Formulation: Results from a Retrospective Cohort Study. Blood, 2015, 126, 5106-5106.	0.6	1

#	Article	IF	Citations
91	Long Term Significance of Response in Multiple Myeloma After Stem Cell Transplantation.. Blood, 2009, 114, 1811-1811.	0.6	1
92	Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar Applicability and Prognosis Impact to Immunophenotypic Response. (A GEM/PETHEMA study),. Blood, 2011, 118, 3951-3951.	0.6	1
93	Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. Blood, 2019, 134, 1852-1852.	0.6	1
94	Deletion of sequences flanking the t(9;22) breakpoint: a secondary genetic event associated with loss of cytogenetic response to interferon in a Philadelphia-positive chronic myeloid leukaemia patient. British Journal of Haematology, 2002, 117, 617-619.	1.2	0
95	Intravenous Busulfan-Melphalan vs Melphalan as Preparative Regimen for Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of a Case-Control Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e287-e288.	0.2	0
96	Matchingâ€adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible. EJHaem, 2020, 1, 481-488.	0.4	0
97	Angioimmunoblastic Tâ€cell lymphoma after acute myeloid leukemia: Alleged common pathogenesis. A case report and literature review. Clinical Case Reports (discontinued), 2020, 8, 3494-3497.	0.2	0
98	Methylen Blue Photoinactivated Plasma vs Fresh Frozen Plasma in Thrombotic Thrombocytopenic Purpura Treatment: A Multicentric Prospective Cohort Study.. Blood, 2007, 110, 1318-1318.	0.6	0
99	Maintenance Treatment after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Multiple Myeloma (MM) with a Unique Weekly Dose of Pegylated Interpheron alpha2b (PegintronÂ®): Preliminary Clinical Results in 30 Patients of a Phase II Multicentric Study.. Blood, 2007, 110, 4822-4822.	0.6	0
100	Patients with Relapsed or Progressive Multiple Myeloma Treated with Lenalidomide in the Compassionate Use Program. Spanish Registry, Preliminary Analysis.. Blood, 2007, 110, 4821-4821.	0.6	0
101	Newly acquired chromosome Abnormalities During Course of CLL: a Retrospective Collection Data From 2 Spanish Centers.. Blood, 2009, 114, 4384-4384.	0.6	0
102	The Addition of Rituximab to CVP (Bagley) + Interferon-Î± as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs. LNH-pro-05 trial). Blood, 2010, 116, 2867-2867.	0.6	0
103	Laser Transmyocardial Revascularization (TMLR) Combined with Autologous Bone Marrow Cells (ABMC) for Diffuse Coronary Disease (DCD). Results In 19 Cases. Blood, 2010, 116, 1181-1181.	0.6	0
104	High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM). Blood, 2011, 118, 630-630.	0.6	0
105	Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC). Blood, 2012, 120, 3949-3949.	0.6	0
106	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). Blood, 2013, 122, 3185-3185.	0.6	0
107	Observational Prospective Registry for the Assessment of the Clinical Impact of Starting Anti-Myeloma Treatment at Biological Relapse. Blood, 2014, 124, 4765-4765.	0.6	0
108	Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience. Blood, 2014, 124, 5897-5897.	0.6	0

#	Article	IF	Citations
109	Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens. Blood, 2014, 124, 2108-2108.	0.6	0
110	Comparison of Assesment of Imaging Response with Magnetic Resonance (MR) and 18fdg-PET/TC in Multiple Myeloma (MM). Single Centre Experience. Blood, 2014, 124, 5707-5707.	0.6	0
111	Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry. Blood, 2015, 126, 4231-4231.	0.6	0
112	Allogeneic Hematopoietic Stem Cell Transplant in Advanced Multiple Myeloma: Experience from a Single Center. Blood, 2015, 126, 5536-5536.	0.6	0
113	Dynamics of Hemorragic Events and Primary Hemostasis Deffects during Treatment with Ibrutinib. Real-Life Experience. Blood, 2016, 128, 4936-4936.	0.6	0
114	Abstract CT154: Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106). , 2019, , .		0
115	Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison. Blood, 2019, 134, 4739-4739.	0.6	0